Markets

Commodities

Currencies

CHMP Recommends Gilead's Trodelvy® Plus Keytruda® in PD-1-Positive First-Line Metastatic Triple-Negative Breast Cancer

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

loader